Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

AlzeCure Pharma’s CEO Martin Jönsson.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

Academic Alliance to Shape the Future of Game Development in Flemingsberg

The game initiative Press Start Game Hub in Flemingsberg has now taken a major step forward in developing a sustainable game development ecosystem by launching its first academic collaboration group: Press Start Academic Group. The first meeting was held in June 2025 and brought together researchers and key figures from some of Sweden’s most prominent game development programs.

The Life Science business of Merck KGaA, Darmstadt, Germany Becomes a Trusted Partner of the Flemingsberg Science Foundation

The Life Science business of Merck KGaA, Darmstadt, Germany, and Flemingsberg Science Foundation collaborate to promote Life Science sector in Flemingsberg. This strategic partnership aims to strengthen development of ATMP (Advanced Therapy Medicinal Products).

Alfa Laval strengthens Flemingsberg – establishes itself in a growing city of the future

In May 2025, Alfa Laval moved into its new office and innovation center, spanning approximately 20,000 square meters, together with around 700 employees. At the same time, the restaurant K-märkt opened, further expanding the range of services available in Flemingsberg. The Royal Swedish Opera and Dramaten, Alfa Laval, Restaurant Billmans, and K-märkt all represent important pieces of the puzzle in the development of Flemingsberg.